In the case of solid tumours, our group previously demonstrated that neuroblastoma cells over-expressing the MYCN oncogene are highly susceptible to loss of PRMT5 [5], prompting this preclinical assessment of the selective PRMT5 inhibitors GSK3203591 and GSK3326593 in neuroblastoma. Here, PRMT5 is linked to neuroblastoma.